MedTrace Logo

A Study to Evaluate Solriktug in Adult Participants With Asthma

NCT06496607 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-05-01

No results posted yet for this study

Summary

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.

Conditions

Interventions

BIOLOGICAL

NSI-8226

Solrikitug

BIOLOGICAL

NSI-8226

Solrikitug

BIOLOGICAL

NSI-8226

Solrikitug

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • DevPro Biopharma

    collaborator INDUSTRY

  • Uniquity One (UNI)

    lead INDUSTRY

Principal Investigators

  • Andrew W Lee, MD · Vice President, Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-26
Primary Completion
2026-06-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06496607 on ClinicalTrials.gov